Category: Regulatory Affairs
Agency information requests carry short, immovable deadlines, and each response means finding evidence across years of documents.
During review, health authorities issue information requests and deficiency letters with response windows measured in days or weeks. Teams must locate the relevant data and prior statements across a sprawling submission archive, then draft responses that are consistent with everything already filed. AI-assisted retrieval and drafting help teams find the right content quickly and produce first drafts, with regulatory professionals owning every final answer.
The hard part of most agency responses is not writing — it is finding: the analysis that answers the question, the places the topic was already addressed, and every prior statement the new response must stay consistent with. Document-intelligence tools index a sponsor's submission archive and correspondence history so a team can query it in plain language and retrieve the relevant passages, tables, and prior responses in minutes instead of days. Drafting support can then assemble a first response built on that retrieved content. The judgment — what position to take, what to concede, what additional analysis to offer — remains entirely with regulatory and clinical experts. The tools compress the search-and-assemble phase so more of a short response window goes to strategy and scientific review rather than document archaeology.
Retrieval quality on your own archive is what matters: ask a vendor to index a real (appropriately controlled) document set and test it against questions your team has actually answered, checking whether it finds the passages the experts know are relevant — and what it misses. Every retrieved statement should carry a citation to its source document and location, because a response built on a misattributed passage is worse than a slow one. Confidentiality and deployment come next: submission archives are among the most sensitive documents a sponsor holds, so examine where the data lives, how access is controlled, and whether private deployment options exist. Finally, probe how drafting is controlled — generated responses need the same review, versioning, and audit discipline as any regulated document.
A practical pilot is retrospective: index the archive for one product and re-run a set of past agency questions through the tool, comparing what it retrieves against what the team actually used in its answers. That measures recall and precision on real questions with known ground truth, without any live deadline at stake. Teams that see strong retrieval typically expand to live use on low-stakes queries before relying on it during a major review cycle.
It indexes the submission archive and correspondence history so teams can retrieve the relevant data, passages, and prior statements in minutes, and it can draft a first response from that retrieved content. The regulatory position and the final answer remain expert judgments — the tool compresses the searching and assembling, not the decision.
It can surface the prior statements a response must align with far faster than manual searching, which reduces the risk of accidental contradiction. But consistency is ultimately a judgment made by people who understand the regulatory strategy — the tool provides the evidence trail, and reviewers confirm the alignment.
It depends on the deployment and controls, not the concept. Examine where documents are processed and stored, who can access the index, whether private-cloud or on-premise options exist, and how the vendor handles confidentiality contractually. Many sponsors restrict initial pilots to a single product's archive under tight access controls.
Ask to test retrieval against past agency questions with known answers, check that every retrieved passage carries a precise source citation, probe deployment and confidentiality options, and review how drafted responses are versioned, reviewed, and audit-trailed. Recall on your own documents matters more than any benchmark.
The U.S. FDA renewed and expanded its long-standing collaboration licensing Certara's Simcyp physiologically-based pharmacokinetic (PBPK) simulator, with hundreds of agency licenses used to inform regulatory review of drug dosing and interactions.
Vendor: Certara · press release (Certara (GlobeNewswire)) · 2021-12-21 — Partner: U.S. FDA
Yseop announced a strategic investment and a milestone of clinical trials supported by its generative AI for regulatory and medical writing.
Vendor: Yseop · press release (Yseop (GlobeNewswire)) · 2023-12-07